+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
SENORES

Senores Pharmaceuticals Share Price

₹1,174.60 -42.4 (-3.48%)
26.54% Fall from 52W High

13 Nov, 2026 3:58 PM (IST)

Senores Pharmaceuticals live price: ₹1,174.60. It opened at ₹1,208 vs previous close ₹1,217; intraday high/low: ₹1,227/₹1,165. The 50 & 200 DMA stand at ₹1,281.90/₹1,162.50.

Senores Pharmaceuticals Performance

  • Today's Low
  • ₹1,165
  • Today's High
  • ₹1,227
  • 52 Week Low
  • ₹706
  • 52 Week High
  • ₹1,599
  • Open Price₹1,208
  • Previous Close₹1,217
  • Volume425,876
  • 50 DMA₹1,281.90
  • 100 DMA₹1,275.50
  • 200 DMA₹1,162.50

Senores Pharmaceuticals Chart

Investment Returns

  • Over 1 Month -10.93%
  • Over 3 Month -21.29%
  • Over 6 Month + 25.91%
  • Over 1 Year + 51.25%

Smart Investing Starts Here Start SIP with Senores Pharmaceuticals for Steady Growth!

Invest Now

Senores Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 40.5
  • PEG Ratio
  • 0.8
  • Market Cap Cr
  • 5,410
  • P/B Ratio
  • 5.6
  • Average True Range
  • 59.5
  • EPS
  • 29
  • Dividend Yield
  • 0
  • MACD Signal
  • -40.7
  • RSI
  • 47.51
  • MFI
  • 27.52

Latest Stock News Updates

Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Senores Pharmaceuticals Limited has informed the exchange regarding transcript of earnings conference call held on October 29, 2026

Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Newspaper Publication

Senores Pharmaceuticals Limited has informed the exchange regarding Newspaper publication extracts of unaudited financial results for the quarter and half year ended September 30, 2026

Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Senores Pharmaceuticals Limited has informed the exchange regarding audio recording of earnings conference call for quarter ended September 30, 2026

Senores Pharmaceuticals Financials

Senores Pharmaceuticals Technicals

EMA & SMA

Current Price
₹1,174.60
-42.4 (-3.48%)
pointer
  • Bearish Moving Average 13
  • Bullish Moving Average 3
  • 20 Day
  • ₹1,217.10
  • 50 Day
  • ₹1,281.90
  • 100 Day
  • ₹1,275.50
  • 200 Day
  • ₹1,162.50

Resistance and Support

1188.87 Pivot Speed
  • R3 1,283.40
  • R2 1,252.60
  • R1 1,234.80
  • S1 1,186.20
  • S2 1,155.40
  • S3 1,137.60

Senores Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-10-29 Quarterly Results
2026-07-27 Quarterly Results
2026-05-14 Audited Results
2026-01-20 Quarterly Results & Others To consider other business matters.
2026-01-07 Others Inter alia, 1. To consider and evaluate proposals for raising funds by way of issue of convertible warrants on preferential basis to the promotors/promoter group.

Senores Pharmaceuticals Shareholding Pattern

45.82%
37.32%
7.36%
6.01%
3.49%

About Senores Pharmaceuticals

Senores Pharmaceuticals is engaged in the business of manufacturing API, trading of pharmaceuticals and allied products and also providing product development services and other management consultancy services. View More
  • NSE Symbol
  • SENORES
  • BSE Symbol
  • 544319
  • ISIN
  • INE0RB801010

Similar Stocks to Senores Pharmaceuticals

Senores Pharmaceuticals FAQs

Senores Pharmaceuticals share price is ₹1,174 As on 13 November, 2026 | 16:40

The Market Cap of Senores Pharmaceuticals is ₹5409.5 Cr As on 13 November, 2026 | 16:40

The P/E ratio of Senores Pharmaceuticals is 40.5 As on 13 November, 2026 | 16:40

The PB ratio of Senores Pharmaceuticals is 5.6 As on 13 November, 2026 | 16:40

The 52 week High & Low of Senores Pharmaceuticals is ₹1599/₹706 respectively As on 13 November, 2026 | 16:40

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23